FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
UNIVERSITÄT BASEL (Switzerland)
Inventor
De Geyter, Christian M.H.R.
Gill, Mark E.
Peters, Antoine Hendrik Felix Marie
Abstract
The present invention provides a method for assessing male fertility by assessing the DNA accessibility in the spermatozoa of a population of spermatozoa from mammalian semen from a subject. The present invention also provides a method of selecting a population of spermatozoa from a subject, wherein the fertility of the population is assessed by assessing the DNA accessibility in the spermatozoa of the population. In addition, the present invention provides a method of in vitro fertilization comprising the step of selecting a population of spermatozoa from a subject by assessing the DNA accessibility in the spermatozoa of spermatozoa populations from the subject.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 700 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in layer 2/3 of mouse cortex of an exogenous gene in a particular population of EGR2-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, said particular population of EGR2-positive cells being characterized in that it also expresses ACTA2, ADORA3 and MYH11.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in mouse cortex of an exogenous gene in a particular population of CNR1-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, said particular population of CNR1-positive cells being characterized in that it also expresses EFHD1, ENPP6 and GJC2.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 500 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in layer 2/3 of mouse cortex of an exogenous gene in a particular population of DLX4-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, said particular population of DLX4-positive cells being characterized in that it also expresses VTN, ABCC9 and CLDN5.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Heindorf, Matthias
Keller, Georg
Abstract
The present invention provides a method of screening for psychoactive agents comprising the steps of a) simultaneously assessing in a subject, the activity of neurons of at least two regions of the deep cortical layers in the absence of a potential psychoactive agent and correlating these activities, b) simultaneously assessing in said subject, the activity of said neurons of said at least two regions of the deep cortical layers in the presence of the potential psychoactive agent and correlating said activities, and c) comparing the correlations obtained in step a) and b), wherein any significant change in the correlation obtained in step b) as compared to the correlation obtained in step a) is indicative of a potential psychoactive activity of said potential psychoactive agent.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 700 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in layer 2/3 of mouse cortex of an exogenous gene in a particular population of CUX1-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, particular population of CUX1-positive cells being characterized in that it also expresses FLT1, CSF3R and CLDN5.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana K.
Saenz De Buruaga Corrochano, Beatriz Lucia
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or of a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression of an exogenous gene in layer 5 cells in mouse cortex when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Saenz De Buruaga Corrochano, Beatriz Lucia
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or of a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression of an exogenous gene in layer 5 pyramidal tract cells in mouse cortex when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Saenz De Buruaga Corrochano, Beatriz Lucia
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or of a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression of an exogenous gene in layer 5 cells in mouse cortex when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Grand, Ralph
Luebke, Marlena
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid comprising more than 220 bp, one or more copy of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and a CpG Observed over Estimated ratio (O/E ratio) larger than 0.6 in the N base pairs (bp) preceding and/or in the N bp following said one or more copy of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, wherein the CpG O/E ratio is determined by counting the number of CpG dinucleotides in the N bp-long sequences surrounding the at least one or more copy of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 and calculating the O/E ratio by multiplying the counted number of CpG dinucleotides by N and dividing the result by the product of the number of C and number of G present in the N bp (N*CpG/(C*G)), wherein N is between 50 and 1000 and is the length, in bp, of the sequence immediately preceding or immediately following said one or more copy of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
UNIVERSITY OF ZURICH (Switzerland)
Inventor
Matthias, Patrick
Wang, Longlong
Plückthun, Andreas
Abstract
The present application provides a recombinant binding protein that specifically binds to HDAC6 and blocks the ubiquitin-engaging zinc finger domain of HDAC6.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 500 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in layer 2/3 of mouse cortex of an exogenous gene in a particular population of DLX4-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, said particular population of DLX4-positive cells being characterized in that it also expresses VTN, ABCC9 and CLDN5.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in mouse cortex of an exogenous gene in a particular population of CNR1-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, said particular population of CNR1-positive cells being characterized in that it also expresses EFHD1, ENPP6 and GJC2.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Heindorf, Matthias
Keller, Georg
Abstract
The present invention provides a method of screening for psychoactive agents comprising the steps of a) simultaneously assessing in a subject, the activity of neurons of at least two regions of the deep cortical layers in the absence of a potential psychoactive agent and correlating these activities, b) simultaneously assessing in said subject, the activity of said neurons of said at least two regions of the deep cortical layers in the presence of the potential psychoactive agent and correlating said activities, and c) comparing the correlations obtained in step a) and b), wherein any significant change in the correlation obtained in step b) as compared to the correlation obtained in step a) is indicative of a potential psychoactive activity of said potential psychoactive agent.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
16.
PROMOTER FOR THE EXPRESSION OF GENES IN PARTICULAR CUX1-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 700 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in layer 2/3 of mouse cortex of an exogenous gene in a particular population of CUX1-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, particular population of CUX1-positive cells being characterized in that it also expresses FLT1, CSF3R and CLDN5.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 700 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in layer 2/3 of mouse cortex of an exogenous gene in a particular population of EGR2-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, said particular population of EGR2-positive cells being characterized in that it also expresses ACTA2, ADORA3 and MYH11.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Schuebeler, Dirk
Grand, Ralph
Abstract
The present invention provides an isolated nucleic acid comprising, operably linked to an heterologous transgene, at least two copies of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, said at least two copies being selected independently from one another.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL (Switzerland)
Inventor
Nelidova, Dasha
Roska, Botond
Abstract
The present inventions relates to a method for vision restoration comprising the steps of expressing a temperature-sensitive transient receptor potential (TRP) channel having an extracellular tag in the retina of a subject and of contacting said retina with a nanomaterial conjugated to a molecule specifically binding to said extracellular tag, wherein said nanomaterial generates heat by absorbing radiations of a specific wavelength. And reagents therefor.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or of a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression of an exogenous gene in agmat-positive cells in layer ⅔ of mouse cortex when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule.
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
22.
Promoter for the specific expression of genes in cells expressing glial fibrillary acidic protein
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in cells expressing glial fibrillary acidic protein of a gene when operatively linked to a nucleic acid sequence coding for said gene.
INSERM - INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
INSTITUT PASTEUR DE TUNIS (Tunisia)
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Orend, Gertraud
Bouhaouala-Zahar, Balkiss
Dhaouadi, Sayda
Hendaoui, Ismaïl
Abstract
aaa is G or A iii) AAGSSWDLILQAYAYDY (SEQ ID NO: 3) as variable heavy (VHH) chain complementarity determining region (CDR)3. The invention further relates to a said single-domain antibody directed against Tenascin-C (TNC) for use as medicament and to a pharmaceutical composition comprising said single- domain antibody directed against Tenascin-C (TNC). The present invention finds application in the therapeutic and diagnostic medical technical fields.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Roska, Botond
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
UNIVERSITY OF ZURICH (Switzerland)
Inventor
Matthias, Patrick
Wang, Longlong
Plückthun, Andreas
Abstract
The present application provides a recombinant binding protein that specifically binds to HDAC6 and blocks the ubiquitin-engaging zinc finger domain of HDAC6.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Juettner, Josephine
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 600 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal endothelial cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Schuebeler, Dirk
Grand, Ralph
Luebke, Marlena
Abstract
The present invention provides an isolated nucleic acid comprising more than 220 bp, one or more copy of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and a CpG Observed over Estimated ratio (O/E ratio) larger than 0.6 in the N base pairs (bp) preceding and/or in the N bp following said one or more copy of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, wherein the CpG O/E ratio is determined by counting the number of CpG dinucleotides in the N bp-long sequences surrounding the at least one or more copy of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 and calculating the O/E ratio by multiplying the counted number of CpG dinucleotides by N and dividing the result by the product of the number of C and number of G present in the N bp (N*CpG/(C*G)), wherein N is between 50 and 1000 and is the length, in bp, of the sequence immediately preceding or immediately following said one or more copy of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Bell, Christie L.
Juettner, Josephine
Krol, Jacek
Mcgee, Terri
Roska, Botond
Abstract
Viral vectors to deliver a heterologous CYP4V2 gene to the retina, e.g., RPE cells of the retina, are provided herein to treat subjects with Bietti crystalline dystrophy.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Bell, Christie L.
Juettner, Josephine
Krol, Jacek
Mcgee, Terri
Roska, Botond
Abstract
Viral vectors to deliver a heterologous CYP4V2 gene to the retina, e.g., RPE cells of the retina, are provided herein to treat subjects with Bietti crystalline dystrophy.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 600 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 800 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule specifically leads to the expression in protoplasmic astrocytes of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule leads to the specific expression of an exogenous gene in photoreceptors when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 550 bp having at least 80% identity to said sequence of SEQ ID NO:1, and uses thereof, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
36.
SYNP194 (PROB15), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Schuebeler, Dirk
Grand, Ralph
Abstract
The present invention provides an isolated nucleic acid comprising, operably linked to an heterologous transgene, at least two copies of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, said at least two copies being selected independently from one another.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Hartl, Dominik
Juettner, Josephine
Krebs, Arnaud
Roska, Botond
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
39.
PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN MÜLLER CELLS
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Roska, Botond
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in Müller cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL (Switzerland)
Inventor
Nelidova, Dasha
Roska, Botond
Abstract
The present inventions relates to a method for vision restoration comprising the steps of expressing a temperature-sensitive transient receptor potential (TRP) channel having an extracellular tag in the retina of a subject and of contacting said retina with a nanomaterial conjugated to a molecule specifically binding to said extracellular tag, wherein said nanomaterial generates heat by absorbing radiations of a specific wavelength. And reagents therefor.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
Friedrich Miescher Institute for BioMedical Research (Switzerland)
Inventor
Hartl, Dominik
Juettner, Josephine
Krebs, Arnaud
Roska, Botond
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Hartl, Dominik
Juettner, Josephine
Krebs, Arnaud
Roska, Botond
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Hartl, Dominik
Juettner, Josephine
Krebs, Arnaud
Roska, Botond
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 150 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or of a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression of an exogenous gene in agmat-positive cells in layer 2/3 of mouse cortex when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Nelidova, Dasha
Roska, Botond
Abstract
The present inventions relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention to a method for expressing an exogenous gene specifically in cells of the retinal pigment epithelium of a primate, this method comprising the step of delivering an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or consisting of a nucleic acid sequence of at least 400 bp having at least 80% overall identity to the sequence of SEQ ID NO:1, to cells of the retinal pigment epithelium of the primate, wherein this isolated nucleic acid molecule specifically leads to the expression of an exogenous gene in cells of the retinal pigment epithelium of primates when a nucleic acid sequence coding for the exogenous gene is operatively linked to this isolated nucleic acid molecule.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Friedrich Miescher Institute for BioMedical Research (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1000 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in cells of the retinal pigment epithelium of a gene when operatively linked to a nucleic acid sequence coding for said gene.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
49.
PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN CELLS EXPRESSING GLIAL FIBRILLARY ACIDIC PROTEIN
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Keller, Georg
Oyibo, Hassana
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in cells expressing glial fibrillary acidic protein of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Bell, Christie L.
Krol, Jacek
Juettner, Josephine
Mcgee, Terri
Roska, Botond
Abstract
Viral vectors to deliver a heterologous CYP4V2 gene to the retina, e.g., RPE cells of the retina, are provided herein to treat subjects with Bietti crystalline dystrophy.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Roska, Botond
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Bell, Christie L.
Krol, Jacek
Juettner, Josephine
Mcgee, Terri
Roska, Botond
Abstract
Viral vectors to deliver a heterologous CYP4V2 gene to the retina, e.g., RPE cells of the retina, are provided herein to treat subjects with Bietti crystalline dystrophy.
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
54.
SYNP166 (PROA36), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN PHOTORECEPTORS
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression of an exogenous gene in photoreceptors when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 600 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule leads to the specific expression of an exogenous gene in photoreceptors when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 550 bp having at least 80% identity to said sequence of SEQ ID NO:1, and uses thereof, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 350 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
61.
SYNP27 (PROB12), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN PROTOPLASMIC ASTROCYTES
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 800 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule specifically leads to the expression in protoplasmic astrocytes of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Hartl, Dominik
Juettner, Josephine
Krebs, Arnaud
Roska, Botond
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in direction selective retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention to a method for expressing an exogenous gene specifically in cells of the retinal pigment epithelium of a primate, this method comprising the step of delivering an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or consisting of a nucleic acid sequence of at least 1500 bp having at least 80% overall identity to the sequence of SEQ ID NO:1, to cells of the retinal pigment epithelium of the primate, wherein this isolated nucleic acid molecule specifically leads to the expression of an exogenous gene in cells of the retinal pigment epithelium of primates when a nucleic acid sequence coding for the exogenous gene is operatively linked to this isolated nucleic acid molecule.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1000 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in cells of the retinal pigment epithelium of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Krol, Jacek
Roska, Botond
Abstract
The present invention to a method for expressing an exogenous gene specifically in cells of the retinal pigment epithelium of a primate, this method comprising the step of delivering an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or consisting of a nucleic acid sequence of at least 400 bp having at least 80% overall identity to the sequence of SEQ ID NO:1, to cells of the retinal pigment epithelium of the primate, wherein this isolated nucleic acid molecule specifically leads to the expression of an exogenous gene in cells of the retinal pigment epithelium of primates when a nucleic acid sequence coding for the exogenous gene is operatively linked to this isolated nucleic acid molecule.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 25/00 - Drugs for disorders of the nervous system
69.
NOVEL METHODS FOR THE TARGETED INTRODUCTION OF VIRUSES INTO CELLS AND TISSUES
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
EIDG. TECHNISCHE HOCHSCHULE ETH (Switzerland)
Inventor
Flaeschner, Gotthold
Müller, Daniel Jobst
Roska, Botond
Schubert, Rajib
Trenholm, Stuart
Abstract
The present invention provides a method of infecting a cell with a virus, said method comprising the step of contacting the cell with a virus attached to a support, said method being characterized in that said support can be attracted by a magnet and in that a magnetic field is used to guide said support comprising said virus to the cell which should be infected by the virus bound to said support.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Hartl, Dominik
Juettner, Josephine
Krebs, Arnaud
Roska, Botond
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 150 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Matthias, Patrick Daniel
Saito, Makoto
Abstract
The present application provides a HDAC6 inhibitor for use in treating a degenerative disease associated with the formation of intracellular granules, wherein said granules are formed by the aggregation of a protein selected from the group comprising APP, Tau, Ataxin-2, hnRNPA1, C9orf72, Lamin A/C, Myotilin, Matrin 3, alpha-synuclein, SOD1, FUS, hnRNPA2B1, VCP, TIA1, Desmin and Huntingtin, and wherein said inhibitor inhibits both the CD1 and CD2 of HDAC6.
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
72.
SYNP159, a promoter for the specific expression of genes in rod photoreceptors
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Hartl, Dominik
Juettner, Josephine
Krebs, Arnaud
Roska, Botond
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Hartl, Dominik
Juettner, Josephine
Krebs, Arnaud
Roska, Botond
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Dalkara, Deniz
Picaud, Serge
Desrosiers, Melissa
Sahel, Jose-Alain
Duebel, Jens
Bemelmans, Alexis
Roska, Botond
Abstract
The present invention relates to a nucleic acid sequence derived from the regulatory region of the human gamma-synuclein gene and having a promoter activity in retinal ganglion cells. The present invention also relates to expression cassettes or vectors comprising said promoter operably linked to a nucleic acid sequence encoding a polypeptide of interest as well as viral particles or host cells comprising said expression cassette or vector. The present invention also relates to the use of said expression cassettes, vectors, viral particles or cells in the treatment of ocular disease, in particular ocular disease associated with retinal ganglion cell or photoreceptor cell degeneration.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
75.
SYNP162, a promoter for the specific expression of genes in rod photoreceptors
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Hartl, Dominik
Juettner, Josephine
Krebs, Arnaud
Roska, Botond
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
76.
Promoter for the specific expression of genes in retinal endothelial cells
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Roska, Botond
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 600 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal endothelial cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Nelidova, Dasha
Roska, Botond
Abstract
The present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61K 9/00 - Medicinal preparations characterised by special physical form
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Roska, Botond
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Roska, Botond
Juettner, Josephine
Teixeira, Miguel
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 700 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in interneurons of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Roska, Botond
Juettner, Josephine
Teixeira, Miguel
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1000 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in interneurons of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Hartl, Dominik
Juettner, Josephine
Krebs, Arnaud
Roska, Botond
Schuebeler, Dirk
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in direction selective retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Gasser, Susan M.
Seeber, Andrew
Hauer, Michael Hermann
Abstract
The present disclosure relates to methods and kits for increasing the frequency of insertion of a nucleotide sequence of interest in a specific chromosomal site within the genome of a eukaryotic cell by modifying the state of chromatin in said cell. In the present disclosure chromatin state may be altered by reducing nucleosomal occupancy by modulating the activity of high-mobility group box (HMGB) proteins.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/90 - Stable introduction of foreign DNA into chromosome
83.
Promoter for the specific expression of genes in Müller cells
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Roska, Botond
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in Müller cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Balya, David
Busskamp, Volker
Lagali, Pamela
Roska, Botond
Abstract
The present invention relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Roska, Botond
Rompani, Santiago
Abstract
The present inventions relates to tools and methods for the treatment of blindness in a patient, wherein a vector comprising a gene coding for a light-sensitive molecule is injected into the lateral geniculate nucleus of the patient..
UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (France)
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Dalkara, Deniz
Picaud, Serge
Desrosiers, Melissa
Sahel, José-Alain
Duebel, Jens
Bemelmans, Alexis
Roska, Botond
Abstract
The present invention relates to a nucleic acid sequence derived from the regulatory region of the human gamma-synuclein gene and having a promoter activity in retinal ganglion cells. The present invention also relates to expression cassettes or vectors comprising said promoter operably linked to a nucleic acid sequence encoding a polypeptide of interest as well as viral particles or host cells comprising said expression cassette or vector. The present invention also relates to the use of said expression cassettes, vectors, viral particles or cells in the treatment of ocular disease, in particular ocular disease associated with retinal ganglion cell or photoreceptor cell degeneration.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Hartl, Dominik
Schuebeler, Dirk
Roska, Botond
Krebs, Arnaud
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Hartl, Dominik
Schuebeler, Dirk
Roska, Botond
Krebs, Arnaud
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Hartl, Dominik
Schuebeler, Dirk
Roska, Botond
Krebs, Arnaud
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 150 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Hartl, Dominik
Schuebeler, Dirk
Roska, Botond
Krebs, Arnaud
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Buehler, Marc
Kowalik, Katarzyna
Shimada, Yukiko
Abstract
The present application relates to a method for the targeted formation of heterochromatin and/or induction of epigenetic gene silencing in a cell using a small RNA, said method comprising the step of inhibiting the Paf1 complex in said cell and the step of contacting said cell with a small RNA targeted to a region of the genome of the cell, said region being the region where heterochromatin formation and/or induction of epigenetic gene silencing should be induced.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Roska, Botond
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO: 1 or a nucleic acid sequence of at least 200 bp having at least 70% identity to the sequence of SEQ ID NO: 1, wherein the isolated nucleic acid molecule specifically leads to the expression in retinal amacrine bipolar cells of a gene when operatively linked to a nucleic acid sequence coding for the gene.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Hendaoui, Ismail
Abstract
The present disclosure relates to a method for treating biliary tract cancer in a subject by inhibiting tenascin W by administering to said subject a therapeutically effective amount of a modulator of said tenascin, for example a specific antibody or a siRNA. The present disclosure also encompasses methods of diagnosing cancer by measuring levels of tenascin-W, as well as method of targeted therapy using anti-tenascin-W antibodies conjugated to therapeutic agents.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Roska, Botond
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 600 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal endothelial cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Juettner, Josephine
Nelidova, Dasha
Roska, Botond
Abstract
The present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Roska, Botond
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in Muller cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Boska, Botond
Juettner, Josephine
Abstract
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in Müller cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
Friedrich Miescher Institute for Biomedical Research (Switzerland)
Inventor
Balya, David
Busskamp, Volker
Lagali, Pamela
Roska, Botond
Abstract
The present inventions relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 14/215 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Halobacteriaceae (F)
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Roska, Botond
Lagali, Pamela
Abstract
An isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO:1, or a nucleic acid sequence of at least 1000 bp having at least 70% identity to the sequence of SEQ ID NO:1. The isolated nucleic acid molecule can lead to the expression of a gene in retinal ON bipolar cells when a nucleic acid sequence coding for a gene is operatively linked to the isolated nucleic acid molecule.
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (Switzerland)
Inventor
Bentires-Alj, Mohamed
Britschgi, Adrian
Abstract
The present invention relates to a method for treating breast cancer in a subject having a breast cancer of the estrogen receptor (ERα) negative type, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the Large Tumor Suppressor Kinase (LATS). Also provided are a si RNA decreasing or silencing the expression of the Large Tumor Suppressor Kinase (LATS), and an antibody specifically binding to the Large Tumor Suppressor Kinase (LATS), for use to treat breast cancer of the estrogen receptor (ERα) negative type.
patents
